Diabetic CKD: a metabolic disease, not just a kidney disease
Decades of insulin resistance force the kidneys to filter glucose-rich, inflammatory blood under high pressure. Over time the filtering units (nephrons) scar, eGFR drops, and protein begins leaking into the urine. Standard care — ACE inhibitors, SGLT2 inhibitors, blood pressure control — slows the decline but rarely reverses it.
How PIR restores kidney function
Physiologic Insulin Resensitization (PIR) restores the cells' ability to respond to insulin. Once kidney cells can use glucose properly again, intra-renal pressure normalizes, inflammation drops, and damaged nephrons regain function. Patients often see eGFR stabilize or improve within months — a result rarely seen in conventional CKD care.
Research published in the American Journal of Biomedical Science & Research documents the protocol used in our clinic and the reproducible improvements it has produced in stage 2–4 CKD.
Who is a candidate?
We see the strongest results in patients with stage 2–4 CKD driven by Type 2 diabetes, insulin resistance, or metabolic syndrome. Patients on dialysis can still benefit from improved metabolic control, energy, and quality of life. We coordinate directly with your nephrologist throughout treatment.
What treatment looks like
After a comprehensive intake and baseline kidney panel, patients begin PIR 2–3 times per week. Most programs run 12–24 weeks depending on starting eGFR. We re-check labs every 4–6 weeks so you can see your progress in real numbers.
Frequently asked questions
What is diabetic chronic kidney disease (CKD)?+
Diabetic CKD is progressive loss of kidney function caused by long-term high blood sugar and insulin resistance. It is the leading cause of kidney failure in the U.S. and is typically tracked by eGFR (estimated glomerular filtration rate) and urinary albumin levels.
Can chronic kidney disease be reversed?+
CKD has traditionally been considered progressive and irreversible. However, recent peer-reviewed case studies — including work published in the American Journal of Biomedical Science & Research — document measurable improvements in eGFR and reductions in proteinuria in CKD patients treated with Physiologic Insulin Resensitization (PIR).
At what CKD stage is PIR most effective?+
PIR shows the strongest results in CKD stages 2–4. Patients with stage 5 (dialysis-dependent) kidney disease may still benefit from improved metabolic control, but reversal becomes less likely. The earlier we intervene, the more kidney function we can preserve.
Will PIR interfere with my dialysis or transplant medications?+
PIR is compatible with dialysis schedules and most post-transplant immunosuppressants. Our physicians coordinate directly with your nephrologist to time treatments safely and monitor kidney markers throughout the protocol.
How does PIR protect the kidneys?+
Insulin resistance forces the kidneys' filtration cells (podocytes) to work in a glucose-starved, inflammatory state. PIR restores normal insulin signaling, reduces hyperfiltration, lowers intra-renal pressure, and decreases protein leakage — addressing the root mechanism of diabetic nephropathy.
What kidney markers do you track during treatment?+
We monitor eGFR, serum creatinine, BUN, urine albumin-to-creatinine ratio (UACR), cystatin C when indicated, A1C, and a comprehensive metabolic panel at baseline and at regular intervals throughout your program.
Can PIR help if I'm not diabetic but have CKD?+
Most CKD outside of polycystic kidney disease has a metabolic component, and insulin resistance is increasingly recognized as a driver of non-diabetic kidney disease. We evaluate each patient individually to determine whether PIR is a fit.
How long before I see improvements in kidney function?+
Lab improvements typically appear within 3–6 months of consistent PIR therapy. eGFR can stabilize or rise, and proteinuria often drops measurably. Energy levels, edema, and blood pressure usually improve before the labs catch up.